Curve Therapeutics’ Post

Recognizing the pervasive and systemic reality of multibillion-dollar losses from late-stage clinical trial failures, Predictive Oncology recently announced the expansion of its live-cell tumor platform to de-risk drug discovery and accelerate pipeline development. The company — leveraging its artificial intelligence and machine learning capabilities —  is now mining its extensive biobank of cryogenically preserved patient-derived live-cell tumor samples, across 137 different tumor types to account for patient heterogeneity ahead of any clinical phase development work. The ability to accelerate drug development timelines would allow pharmaceutical companies to make critical go/no go decisions, redirect resources or reprioritize R&D efforts more quickly and efficiently. To learn more about how Predictive Oncology has successfully demonstrated its ability to increase the Probability of Technical Success (PTS) by incorporating real-world applications, please visit https://lnkd.in/gvnTrtJ5. For investors, click here https://lnkd.in/gb9BepZA. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech #lifesciences

Efficacy and Toxicity Testing using Inovotion's CAM model (#3/6)   Pharmaceutical chemical and biology researchers need to develop new methods and models to improve the predictivity of preclinical discovery phases, increase the number of high-value molecules in clinic, and adopt 3Rs practices. INOVOTION’s unique in vivo technology will allow you to test more drug candidates, without increasing your costs.   INOVOTION performs routine in vivo efficacy and toxicity evaluations of anticancer drug candidates and has standardized its assay for over 55 tumor models and associated reference molecules.  We carry out 25000 human xenografts each year, on standardized human cancer lines, organoids, PDX, biopsies, and more. We can provide extensive, simultaneous readouts for larger experimental groups than with other models (eg 10-15 individuals). We have over 180 clients in 26 countries, in hospitals, biotechs, and large and small pharma companies.   Contact us so that we can give you further information and discuss your specific project. https://lnkd.in/gWQJncb     #oncology   #preclinical    #drugdiscovery

At the dawn of 2024, there’s a sense of renewed optimism in the biotech sector despite recent sector-specific challenges. This week, the J.P. Morgan Health Care Conference witnessed strong deal-making activity. Here's how #Biotech bounces back at JPM 2024: https://lnkd.in/eNsKYR7N #ObesityDrugs #AntibodyDrugs #funding #RandD #ClinicalDevelopment #biotechnology #oncology

Thoughts on this? >> Apollomics plans to lay off staff, narrow focus for lung cancer trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #productmarketing #healthcare

🚀 One-shot design of a differentiated BRD9 inhibitor using the QuanMol ReDefine platform Bromodomain-containing protein 9 (BRD9), a promising therapeutic target in cancer treatment, has been the focus of many discovery programs, including published works by Boehringer Ingelheim, GSK, AstraZeneca, and Genentech, among others. Due to its compact protein structure, developing novel inhibitors for BRD9 with a high potency poses significant challenges. QuanMol’s one-shot de novo design of a novel BRD9 inhibitor sets a new standard of in silico discovery with: ■ 60 nM Potency: Validated by SPR, this represents a significant advancement over the usual micromolar activity found in virtual screenings and is even more potent than some advanced compounds. ■ Unique Scaffold & Binding Mode: Our approach introduces a novel chemical structure with differentiated binding interactions. ■ Highly Efficient Precision Design: Created precisely in just one attempt and within two hours, demonstrating our platform's capability to significantly accelerate drug discovery. At QuanMol, we aim to narrow the translational gap in small-molecule therapeutics across the industry, enhancing your R&D efficiency with our discovery solutions. This achievement with BRD9 is a testament to our mission and the capability of the AI-powered QuanMol ReDefine platform. Interested in a partnership? Let's connect at connect@quanmol.com. #biotech #pharma #ai #drugdiscovery #drugdesign #biology #quanmol #quanmoltech

Thoughts on this? >> Apollomics plans to lay off staff, narrow focus for lung cancer trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech

What an incredible day at the 22nd San Diego Biopharma Conference in the beautiful San Diego, full of thought leadership conversations. Dr. Qingcong Lin, president of Medicilon USA Corp., gave a wonderful presentation "Challenges of #ADC Preclinical #DMPK and Safety Evaluation" during the conference. #Medicilon specializes in ADC, a revolutionary approach to cancer treatment. Our services encompass the entire ADC development process, including: 🔹 ADC Chemistry: Payload and linker R&D, antibody-drug conjugation 🔹In Vitro Evaluation: Binding assays, internalization, cell cycle & apoptosis analysis, bystander effect studies 🔹In Vivo Evaluation: Pharmacodynamics, pharmacokinetics, toxicology studies Our team has successfully supported 28 #IND approvals for ADC therapies, underscoring our leadership in this field. 🔗Click to see more details: https://lnkd.in/dPc8mGSF #SABPA #Medicilon #Drugdiscovery #Preclinical

What an incredible day at the 22nd San Diego Biopharma Conference in the beautiful San Diego, full of thought leadership conversations. Dr. Qingcong Lin, president of Medicilon USA Corp., gave a wonderful presentation "Challenges of #ADC Preclinical #DMPK and Safety Evaluation" during the conference. #Medicilon specializes in ADC, a revolutionary approach to cancer treatment. Our services encompass the entire ADC development process, including: 🔹 ADC Chemistry: Payload and linker R&D, antibody-drug conjugation 🔹In Vitro Evaluation: Binding assays, internalization, cell cycle & apoptosis analysis, bystander effect studies 🔹In Vivo Evaluation: Pharmacodynamics, pharmacokinetics, toxicology studies Our team has successfully supported 28 #IND approvals for ADC therapies, underscoring our leadership in this field. 🔗Click to see more details: https://lnkd.in/dPc8mGSF #SABPA #Medicilon #Drugdiscovery #Preclinical

The landscape of early-phase drug development is evolving rapidly, especially for small- to mid-sized biotech companies. With the introduction of Project Optimus, costs and complexities have surged, making it harder than ever to secure funding and complete trials. Based on recent conversations at hubXChange Immuno-Oncology, read Meredith M.’s blog post about how biotech companies can navigate challenges and continue to innovate with Catalyst Oncology. #Biotech #DrugDevelopment #ClinicalTrials #HubXChange #EarlyPhaseOncology https://hubs.li/Q02SwHGz0

🔥🚀 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐌&𝐀 𝐄𝐱𝐩𝐥𝐨𝐬𝐢𝐨𝐧 𝐢𝐧 2024! 🚀🔥 🤔 Did you know the number of biopharma M&A deals has more than doubled in Q1 of 2024 compared to last year? From 6 to 13, totaling 47 in the last twelve months! 📈 🎉 𝐁𝐢𝐠 𝐌𝐨𝐯𝐞𝐬 𝐢𝐧 𝐁𝐢𝐠 𝐏𝐡𝐚𝐫𝐦𝐚: • AstraZeneca shakes up oncology with deals for Fusion Pharmaceuticals & Gracell Biotechnologies! 🧬 • Merck Life Science acquires T-cell magic from Harpoon Therapeutics! 🎯 🌟 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤’𝐬 𝐇𝐞𝐚𝐝𝐥𝐢𝐧𝐞𝐫𝐬: • Takeda could spend up to $1.2 billion on a new cancer fighter with Kumquat Biosciences Inc.! 🛡️ • Boehringer Ingelheim and Ochre Bio tackle liver disease with a billion-dollar RNA therapy bet! 🧪 • Ipsen is investing $1.8 billion in neuroscience R&D with Skyhawk Therapeutics! 🧠 🌐 With Big Pharma's unwavering interest, 2024 is set to be a groundbreaking year for biotech M&A. What’s your take? Could this be the boost we've been waiting for in innovation and competition? 💡 #Biotech #MergersAndAcquisitions #Innovation #PharmaIndustry #FutureOfPharma